₩4,100.00 ($3.03)

-55.00 (-1.32%)

Weekly Expected Move ±3.7%

₩3800 ₩3950 ₩4100 ₩4250 ₩4400

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 47 · ₩404.5B mcap · 68M float · 0.676% daily turnover

Revenue

$200.7B +25.4% ▲

5Y CAGR: +3.4%

Gross Profit

$95.7B +28.8% ▲

5Y CAGR: +6.0%

Operating Income

$14.2B +775.2% ▲

5Y CAGR: +28.6%

Net Income

$12.6B +576.0% ▲

EPS (Diluted)

$127.43 +430.2% ▲

EBITDA

$19.7B +157.7% ▲

5Y CAGR: +54.8%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$182.5B	$190.9B	$125.9B	$160.1B	$200.7B
YoY Growth	+7.6%	+4.6%	-34.0%	+27.1%	+25.4%
Cost of Revenue	$106.7B	$111.5B	$75.9B	$85.7B	$105.0B
Gross Profit	$75.8B	$79.4B	$50.0B	$74.3B	$95.7B
Gross Margin	41.5%	41.6%	39.7%	46.4%	47.7%
R&D Expenses	$22.5B	$24.3B	$34.6B	$23.4B	$0
SG&A Expenses	$13.5B	$19.8B	$22.1B	$16.8B	$0
Operating Expenses	$70.1B	$79.7B	$87.5B	$72.7B	$81.6B
Operating Income	$5.6B	-$231M	-$37.5B	$1.6B	$14.2B
Operating Margin	3.1%	-0.1%	-29.8%	1.0%	7.1%
Interest Expense	$1.4B	$1.8B	$3.8B	$6.5B	$3.9B
Income Before Tax	$3.8B	-$1.0B	-$39.6B	-$3.0B	$6.4B
Tax Expense	$6.6B	$3.2B	-$5.2B	$489M	-$6.0B
Net Income	-$917M	-$2.5B	-$31.3B	-$2.6B	$12.6B
Net Margin	-0.5%	-1.3%	-24.9%	-1.6%	6.3%
EPS (Diluted)	$-13.39	$-36.15	$-457.67	$-38.59	$127.43
EBITDA	$11.4B	$5.8B	-$31.5B	$7.6B	$19.7B
Shares Outstanding	68M	68M	68M	68M	99M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$42.6B	$46.2B	$47.8B	$42.6B	$47.8B	$62.5B	$47.8B	$57.0B
Cost of Revenue	$22.3B	$24.8B	$27.1B	$23.8B	$28.4B	$28.8B	$27.9B	$31.4B
Gross Profit	$20.3B	$21.4B	$20.7B	$18.8B	$19.5B	$33.7B	$19.9B	$25.6B
Gross Margin	47.6%	46.3%	43.4%	44.1%	40.7%	53.9%	41.7%	45.0%
R&D Expenses	$5.7B	$5.8B	$4.5B	$4.4B	$4.2B	$7.8B	$6.0B	$0
SG&A Expenses	$11.3B	$4.8B	$4.7B	$16.8B	$14.2B	$17.8B	$4.2B	$15.9B
Operating Expenses	$17.1B	$19.4B	$17.2B	$16.8B	$18.5B	$25.6B	$18.8B	$24.2B
Operating Income	$3.2B	$2.0B	$3.0B	$2.0B	$979M	$8.2B	$1.1B	$1.4B
Operating Margin	7.5%	4.2%	6.3%	4.7%	2.0%	13.0%	2.3%	2.5%
Interest Expense	$1.5B	$579M	$5.4B	$1.7B	$679M	-$3.9B	$1.1B	$1.1B
Income Before Tax	$1.4B	-$2.1B	-$323M	$2.5B	$1.2B	$3.6B	$2.1B	$1.8B
Tax Expense	$1.3B	-$3.9B	-$212M	-$3.9B	-$272M	-$1.2B	$924M	$448M
Net Income	$155M	$1.8B	-$69M	$6.4B	$1.5B	$4.8B	$1.2B	$1.4B
Net Margin	0.4%	4.0%	-0.1%	15.1%	3.2%	7.7%	2.5%	2.5%
EPS (Diluted)	$2.00	$26.57	$-1.01	$93.89	$11.00	$23.43	$11.93	$14.00
EBITDA	$4.1B	$5.1B	$4.2B	$20.1B	$2.4B	$9.7B	$2.8B	$1.9B
Shares Outstanding	77M	68M	68M	68M	139M	205M	97M	98M

003000.KS KSC